Neurotrope Inc (NTRP) 0.6500 $NTRP
Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference
PR Newswire - Mon Jul 20, 10:08AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company"
will be showcasing bryostatin as a potential treatment for Alzheimer's Disease at the Alzheimer's Association International Conference(R) (AAIC) being held July 18-23, 2015, in Washington, DC.
Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
PR Newswire - Wed Jun 24, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary ("Neurotrope", will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease ("SOAR-NPC".
Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C
PR Newswire - Fri Jun 12, 7:30AM CDT
Neurotrope Bioscience, Inc. (Neurotrope or the Company), the operating subsidiary of Neurotrope, Inc. (OTCQB: NTRP) today announced the Company will present the findings of in vitro studies of bryostatin's effects on Niemann Pick Type C1 cells (NPC1 cells) at the annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C research to be held on June 11 -13, 2015 at the University of Notre Dame. The Company's presentation will take place on Friday, June 12, at 2:30 pm Eastern time.
Neurotrope Tackling Alzheimer's, Other Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Mon May 18, 4:21PM CDT
Neurotrope Joins National Organization for Rare Disorders (NORD) Corporate Council
PR Newswire - Thu Apr 23, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that, based upon its work in orphan drug indications, it has been invited to join the National Organization for Rare Disorders (NORD) as a member of the NORD Corporate Council. NORD is a leading independent, non-profit organization committed to the identification, treatment, and cure of rare disorders.
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 43.41 (+0.29), LXRX: 13.20 (+0.61), TROV: 6.24 (-0.19), CYTR: 2.82 (+0.22), BMY: 59.22 (+0.47), ARNA: 2.86 (+0.15)
Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
PR Newswire - Mon Apr 20, 6:55AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA" to fund a pre-clinical Fragile X Syndrome ("FXS" behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile.
Neurotrope's bryostatin an Orphan Drug for fragile X syndrome
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 7:41AM CDT
Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 43.41 (+0.29), INO: 7.34 (+0.23), GILD: 109.63 (+2.38), RGLS: 8.91 (+0.22), ALKS: 70.95 (+1.28)
Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome
PR Newswire - Thu Apr 09, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, (the "Company" has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its lead proprietary drug candidate, bryostatin, in the treatment of Fragile X Syndrome (FXS).
Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:35AM CDT
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
INO: 7.34 (+0.23), OREX: 2.44 (-0.44), CAPNU: (), ARNA: 2.86 (+0.15), CAPN: 2.45 (unch)
Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company" has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company's compound bryostatin-1 for the treatment of Alzheimer's disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer's disease.
Advances in Biotech Expanded Studies Lead to Cutting-Edge Therapeutic Treatments - Company Announces Positive Final Results in Treatment for Alzheimer's Disease
PR Newswire - Tue Mar 17, 7:35AM CDT
The latest medical projects aimed to prevent illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), TG Therapeutics, Inc. (NASDAQ: TGTX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and Actavis plc (NYSE: ACT)
INO: 7.34 (+0.23), ACT: 298.98 (-2.94), LXRX: 13.20 (+0.61), TGTX: 11.83 (+0.37)
Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease
PR Newswire - Tue Mar 17, 6:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced secondary and exploratory endpoint results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer's disease (AD). Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCe). The Company is approaching the treatment of Alzheimer's disease through the activation of PKCe. In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration.
Neurotrope Forms Clinical Advisory Board to Support Alzheimer's Disease Program
PR Newswire - Wed Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.
Neurotrope to Present at the Biotech Showcase 2015 Conference
PR Newswire - Wed Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 14, 2015.
IPOs and Transactions Week in Review: December 1 - 5
PR Newswire - Tue Dec 09, 9:30AM CST
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
PGLC: 4.69 (-0.06), IPWR: 8.00 (unch)
Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
PR Newswire - Thu Nov 20, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) announced today that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI).
Neurotrope Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Development and Chief Medical Officer
PR Newswire - Thu Nov 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that Warren W. Wasiewski, M.D., F.A.A.P. has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President, Development and Chief Medical Officer, effective immediately. Dr. Wasiewski replaces Dr. Richard Scheyer, who had served as Chief Medical Officer since January 2014.
ALXN: 171.93 (+0.28)
Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
PR Newswire - Thu Sep 18, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board. He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013.
Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference
PR Newswire - Mon Jul 20, 10:08AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company"
will be showcasing bryostatin as a potential treatment for Alzheimer's Disease at the Alzheimer's Association International Conference(R) (AAIC) being held July 18-23, 2015, in Washington, DC. Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
PR Newswire - Wed Jun 24, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary ("Neurotrope"
, will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease ("SOAR-NPC". Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C
PR Newswire - Fri Jun 12, 7:30AM CDT
Neurotrope Bioscience, Inc. (Neurotrope or the Company), the operating subsidiary of Neurotrope, Inc. (OTCQB: NTRP) today announced the Company will present the findings of in vitro studies of bryostatin's effects on Niemann Pick Type C1 cells (NPC1 cells) at the annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C research to be held on June 11 -13, 2015 at the University of Notre Dame. The Company's presentation will take place on Friday, June 12, at 2:30 pm Eastern time.
Neurotrope Tackling Alzheimer's, Other Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Mon May 18, 4:21PM CDT
Neurotrope Joins National Organization for Rare Disorders (NORD) Corporate Council
PR Newswire - Thu Apr 23, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that, based upon its work in orphan drug indications, it has been invited to join the National Organization for Rare Disorders (NORD) as a member of the NORD Corporate Council. NORD is a leading independent, non-profit organization committed to the identification, treatment, and cure of rare disorders.
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 43.41 (+0.29), LXRX: 13.20 (+0.61), TROV: 6.24 (-0.19), CYTR: 2.82 (+0.22), BMY: 59.22 (+0.47), ARNA: 2.86 (+0.15)
Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
PR Newswire - Mon Apr 20, 6:55AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA"
to fund a pre-clinical Fragile X Syndrome ("FXS" behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile. Neurotrope's bryostatin an Orphan Drug for fragile X syndrome
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 7:41AM CDT
Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 43.41 (+0.29), INO: 7.34 (+0.23), GILD: 109.63 (+2.38), RGLS: 8.91 (+0.22), ALKS: 70.95 (+1.28)
Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome
PR Newswire - Thu Apr 09, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, (the "Company"
has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its lead proprietary drug candidate, bryostatin, in the treatment of Fragile X Syndrome (FXS). Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:35AM CDT
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
INO: 7.34 (+0.23), OREX: 2.44 (-0.44), CAPNU: (), ARNA: 2.86 (+0.15), CAPN: 2.45 (unch)
Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company"
has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company's compound bryostatin-1 for the treatment of Alzheimer's disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer's disease. Advances in Biotech Expanded Studies Lead to Cutting-Edge Therapeutic Treatments - Company Announces Positive Final Results in Treatment for Alzheimer's Disease
PR Newswire - Tue Mar 17, 7:35AM CDT
The latest medical projects aimed to prevent illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), TG Therapeutics, Inc. (NASDAQ: TGTX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and Actavis plc (NYSE: ACT)
INO: 7.34 (+0.23), ACT: 298.98 (-2.94), LXRX: 13.20 (+0.61), TGTX: 11.83 (+0.37)
Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease
PR Newswire - Tue Mar 17, 6:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced secondary and exploratory endpoint results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer's disease (AD). Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCe). The Company is approaching the treatment of Alzheimer's disease through the activation of PKCe. In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neurodegeneration.
Neurotrope Forms Clinical Advisory Board to Support Alzheimer's Disease Program
PR Newswire - Wed Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.
Neurotrope to Present at the Biotech Showcase 2015 Conference
PR Newswire - Wed Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 14, 2015.
IPOs and Transactions Week in Review: December 1 - 5
PR Newswire - Tue Dec 09, 9:30AM CST
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
PGLC: 4.69 (-0.06), IPWR: 8.00 (unch)
Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
PR Newswire - Thu Nov 20, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) announced today that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI).
Neurotrope Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Development and Chief Medical Officer
PR Newswire - Thu Nov 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that Warren W. Wasiewski, M.D., F.A.A.P. has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President, Development and Chief Medical Officer, effective immediately. Dr. Wasiewski replaces Dr. Richard Scheyer, who had served as Chief Medical Officer since January 2014.
ALXN: 171.93 (+0.28)
Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
PR Newswire - Thu Sep 18, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board. He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013.
